Molecular - genetic diagnosis
A new direction development of the group of companies Alkor Bio – one of the most technologically successful companies manufacturing ELISA diagnostic kits in the North-West Region of Russian Federation began in 2007. The holding company started developing and producing PCR test-systems for hereditary diseases diagnostics.
At the present time the company carries out investigations in the field of multifactorial human diseases, such as osteoporosis, cardiovascular diseases, mental disorders and develops test systems for diagnostics of these and other significant diseases including mucoviscidosis based on DNA-microarray method. The group of companies Alkor Bio’s project CF25-array is the test system for detection mutations in CFTR genebased on DNA-microarray method. This diagnostic system intended for diagnostic of cystic fibrosis became the winner of the competition for the award of the St. Petersburg Government for the best innovative project implemented within a cluster in the nomination “Best Innovative Project in the field of medicine, biotechnology and pharmaceutical industries” in 2010.
Rapid development of high-throughput genetic research made it possible to reappraise the approaches to obtaining information on the human genome. Development of diagnostic solutions based on next-generation sequencing has become one of the priority directions of research in field of molecular diagnostics in Alkor Bio (read more)
The diagnostic kit OsteoGENE-M is the unique development of the group of companies Alkor Bio intended for testing of genetic predisposition to bone diseases (osteoporosis, arthrosis, and secondary osteoporosis). The kit enables to screen genetic polymorphism quickly and effectively with the purpose of early revealing risk groups of osteoporosis and other diseases of a bone tissue and estimate of bone mineral density loss. In 2009 the project took the 2nd place in the competition of the St. Petersburg Government for the best innovative project in St. Petersburg.
The group of companies Alkor Bio also developed diagnostic kits ThromboGENE-RT and PharmacoGENE-CYP2C9 and PharmacoGENE-VKORC1
Diagnostic kit ThromboGENE can be used in clinical diagnostics for revealing hereditary thrombophilia and risk estimation of deep venous thrombosis and pulmonary embolism. Increased genetic risk of thromboses with moderate influence of adverse environmental factors can cause severe complications up to pulmonary embolism. Revealing of high risk groups will enable to begin prevention of disease in presymptomatic period.
Diagnostic kits PharmacoGENE-CYP2C9 and PharmacoGENE-VKORC1 can be used in clinical diagnostics for determination of individual susceptibility to indirect anticoagulants for the purpose of drug dose correction. Introduction of this method into medical practice will provide a significant opportunity for prevention of complications and the appointment of an adequate therapy in thrombophilic pathologies.
Summary of the group of companies Alkor Bio’s innovation projects on molecular-genetic diagnosis: Development of test system for cystic fibrosis diagnostics with mutations analysis in CFTR gene using DNA-microarrays.
The development of the unique diagnostic method for mutations detection in CFTR gene using DNA-microarrays is the main element of this project novelty providing the opportunity of effective neonatal screening for cystic fibrosis. Introduction of this method into medical practice will provide a significant opportunity for early identification of carriers of cystic fibrosis mutations.